Skip to main content
OpenTrials
Completed

NCT Number: NCT02901587

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

The purpose of this study is to investigate the effect of Lu AF35700 on electrical activity in the heart as measured on an electrocardiogram (ECG) in patients with schizophrenia or schizoaffective disorder after 6 weeks of treatment

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

US1104

Long Beach, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient is able by her/himself to provide informed consent to participate in the study
  • The patient has a primary diagnosis of schizophrenia or schizoaffective disorder (DSM-5™ criteria)
  • The patient has BMI ≤35 kg/m2
  • The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≤4 (moderately ill)
  • PANSS total score ≤ 80 and a score ≤4 (moderate) on the PANSS items, P7 (hostility) and G8 (uncooperativeness)
  • The patient is willing to be hospitalized for up to 8 weeks
  • The patient is generally healthy based on medical history, physical examination, vital signs, ECG, and laboratory tests.
  • The patient agrees to protocol-defined use of effective contraception

Exclusion criteria

´

  • The patient experienced acute exacerbation of psychosis requiring hospitalization within the last 3 months or required change in medication due to exacerbation of psychosis within the last 8 weeks
  • The patient has met moderate or severe co-morbid Substance Abuse Disorder DSM-5™ criteria in the last 3 months
  • The patient is at significant risk of harming her/himself or others in the opinion of the investigator or according to Columbia Suicide Severity Rating Scale (C-SSRS)
  • The patient has tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV)

Other protocol defined inclusion and exclusion criteria may apply

Treatment and study plan

Lu AF35700 (10 mg/day)

Drug

tablets for oral administration once daily

Lu AF35700 (30 mg/day)

Drug

tablets for oral administration once daily

Quetiapine (Seroquel XR® 800 mg/day)

Drug

tablets for oral administration once daily

Primary outcomes

  1. Change from time-matched baseline on day 1, 21, and 42 in QTcF

    Time frame: Before dose to 10 hours post dose

Sponsors and collaborators

Lead sponsor

H. Lundbeck A/S

Industry

Registry information

Official study title

Interventional, Randomised, Double-blind, Parallel-group, Active-control, Multiple-dose Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Sep 15, 2016
Registry last updated
Sep 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.